Evidence map›Paper›PMID 40389718›Full record

ArticleScientific reports2025

Fungus-targeted nanomicelles enable microRNA delivery for suppression of virulence in Aspergillus fumigatus as a novel antifungal approach.

Tatsuya Inukai, Rikuto Watanabe, Yoshiki Murakami, Horacio Cabral, Masahiko Kuroda, Shigeki Nakamura

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tatsuya InukaiDepartment of Microbiology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.
Rikuto WatanabeDepartment of Microbiology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.
Yoshiki MurakamiDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Horacio CabralDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Masahiko KurodaDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Shigeki NakamuraDepartment of Microbiology, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan. shigenak@tokyo-med.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspergillus fumigatus, which causes aspergillosis, has developed resistance to azole antifungal agents in recent years. As only three main classes of antifungal drugs are available, the development of novel therapeutic strategies is crucial. We aimed to control the expression of virulence factors by introducing microRNAs (miRNAs) into fungi as an innovative therapeutic approach. To test our hypothesis, we selected miRNA mimics targeting alb1, which is involved in the synthesis of 1,8-dihydroxynaphthalene (DHN)-melanin, a virulence factor of A. fumigatus, and transfected them into the protoplast of the fungus, resulting in a two-fold reduction in alb1 expression. Next, we created a 3×HA-tagged Alb1 protein (Alb1-HAp)-expressing strain and confirmed the regulation of translation using western blotting with an anti-HA antibody. The protein amount of Alb1-HAp was reduced by one-third after the introduction of the miRNA. Moreover, the reduction in melanin after miRNA transfection promoted the killing of fungus by hydrogen peroxide-induced oxidative stress and sensitised the fungus to neutrophil attack. Additionally, by loading miRNAs into a fungus-targeted delivery system, we demonstrated the potential of transferring miRNAs into intact fungal cells in vitro. These results indicate the potential of miRNAs to regulate target virulence factors in fungi, leading to the development of novel therapies.

Indexed as

Antifungal AgentsAspergillus fumigatusMicroRNAsAspergillosisFungal ProteinsHumansMelaninsOxidative StressVirulenceVirulence FactorsAntifungal AgentsFungal ProteinsMelaninsMicroRNAsVirulence FactorsAspergillus fumigatusDrug delivery systemsMicroRNAs (miRNAs)RNA therapeutics

Identifiers

PMID40389718
PMCPMC12089607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.